Polifeprosan 20, 3.85% Carmustine Slow Release Wafer in Malignant Glioma: Patient Selection and Perspectives on a Low-Burden Therapy

Patient Preference and Adherence - New Zealand
doi 10.2147/ppa.s93020
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Polifeprosan 20, 3.85% Carmustine Slow-Release Wafer in Malignant Glioma: Evidence for Role in Era of Standard Adjuvant Temozolomide

Core Evidence
MedicineReviewsReferencesPharmacology
2012English

Impact of Novel Antifibrotic Therapy on Patient Outcomes in Idiopathic Pulmonary Fibrosis: Patient Selection and Perspectives

Patient Related Outcome Measures
2018English

Gene Therapy for Malignant Glioma

Molecular and Cellular Therapies
2014English

Gene Therapy for Malignant Glioma

Japanese Journal of Neurosurgery
SurgeryNeurology
2003English

Oncolytic Viral Therapy of Malignant Glioma

Neurotherapeutics
NeurologyPharmacology
2009English

Hysterosalpingo-Foam Sonography: Patient Selection and Perspectives

International Journal of Women's Health
GynecologyOncologyMidwiferyMaternityObstetrics
2016English

Targeting Therapy for Malignant Glioma by Means of Immunoliposomes.

Drug Delivery System
Pharmaceutical Science
1996English

Tumor Burden and Liver Function in HCC Patient Selection for Selective Internal Radiation Therapy: SARAH Post-Hoc Study

Future Oncology
MedicineCancer ResearchOncology
2020English

Transcatheter Left Atrial Appendage Occlusion: Patient Selection and Perspectives

Research Reports in Clinical Cardiology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy